Plasma Liver Enzymes Status in Sudanese Rheumatic Arthritis Patients Treated With Methotrexate

Nada Yousif Awad Alla Hassan; Maissa. K. Albagir; Nassr Eldin M.A Shrif

Authors

Nada Yousif Awad Alla Hassan Department of Clinical chemistry- Faculty of Medical Laboratory SciencesAlneelain University–Sudan
Maissa. K. Albagir Department OF Clinical chemistry- Faculty of Medical Laboratory SciencesAlzaeim Alazhary University–Sudan
Nassr Eldin M.A. Shrif Department OF Clinical Chemistry- Faculty of Medical Laboratory SciencesAlzaeim Alazhary University–Sudan.

Keywords:

Methotrexate (MTX), Rheumatoid arthritis (RA), Aspartate transaminase (AST), Alanine transaminase (ALT), Alkaline phosphatase (ALP)

Abstract

Background: Methotrexate, a drug used for rheumatic arthritis treatment is suspected to has hepatotoxicity. Objectives: This study aimed to assess liver enzymes activity in plasma as indicator of MTX hepatotoxicity in RA Sudanese patients. Methodology: It is a Descriptive cross sectional study, conducted in Khartoum state from January to September 2016 in RA patients treated with MTX, the plasma AST, ALT and ALP activities were measured in study groups. Then, the Generated data analyzed using the statistical package (SPSS). Result: Plasma AST, ALT activities were higher in MTX treated group than healthy group. Plasma ALP activity was not significantly differ between the study groups. Conclusion: MTX increases plasma AST and ALT activity in RA patients, but it has no
effect on plasma ALP.

Downloads

Download data is not yet available.

References

Adel Rezaei Moghadam, Soheil Tutunchi, Ali Namvaran-Abbas-Abad, Mina Yazdi,Fatemeh Bonyadi, Daryoush Mohajeri, Mohammad Mazani, Hassan Marzban,Marek J. Łos and Saeid Ghavami, B.M.C. 2015. Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress. The official J. Int. Soc. Compl. Med. Res., (ISCMR). 15: 246 https://doi.org/10.1186/s12906-015-0773-6).

Ali, N., Rashid, S., Nafees, S., Hasan, S.K. and Sultana, S. 2014. Beneficial effects of Chrysin against Methotrexate-induced hepatotoxicity via attenuation of oxidative stress and apoptosis. Mol. Cell. Biochem., 385(1–2): 215–23.

Cohen, S., Cannon, G.W., Schiff, M., et al., 2001. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum., 44(9):1984–1992.

Cronstein, B.N. 2005. Low–dose methotrexate: A Maintay in the Treatment of Rheumatoid arthritis. Pharma. Rev., 57 (2):163-172.doi: 10.1124/pr.57.2.3. PMID 15914465.

Kolli, V., Natarajan, K., Isaac, B., Selvakumar, D. and Abraham, P. 2013. Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis. Hum. Exp. Toxicol., 33(10):1051–65. 0960327113515503.

Lewis, J.H. and Schiff, E. 1988. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on FDA-related matters. American College of Gastroenterology. American J. Gastroent., 83:1337.

Lopez–Olive ma, 2014. Methotrexate for treating Rheumatoid arthritis. Coch. Data. Sys. Rev., (6): Art. NO: CD000957.

Moss, D.W. 1997. Physiochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells. Clin. Chim. Acta., 257(1):133-40.

Pablos, J.L. and Canete, J.D. 2013. Immunopathology of rheumatoid arthritis. Curr. Top. Med Chem., 13(6): 705-11.

Ramaiah, S.K. 2007. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem. Toxicol., 45(9): 15517.

Rej, R. 1989. Aminotransferases in disease. Clin. Lab. Med., 9(4):667-87.

Smolen, Josef, S., Aletaha, Daniel, McInnes and Iain, B. 2016. Rheumatoid arthritis.

Lancet., 388 (10055): 2023–2038. PMID 27156434. doi:10.1016/S0140-6736(16)30173-8.

Solomon, D.H. 2014. Comparative cancer risk associated with methotrexate, other nonbiologic and biologic disease-modifying anti-rheumatic drugs. Semin. Arthritis Rheum.,43 (4): 489–97. PMID 24012043.

Tian, H. and Cronstein, B.N. 2007. Understanding the mechanisms of action of methotrexate. Bull. NYU. Hosp. Jt. Dis., 65(3):168–73.

Velayudham, L.S. and Farrell, G.C. 2003. Drug-induced cholestasis. Expert Opin. Drug.Saf., 2(3):287-304.

Visser, K., Katchamart, W., Loza, E., Martinez-Lopez, J.A., Salliot, C. and Trudeau, J.2009. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum Dis., 68:1086-1089 pp. http://dx.doi.org/10.1136/ard.2008.094474

Zimmerman, H.J. 1999. Methotrexate. Oncotherapeutic and immunosuppressive agents. In: Zimmerman, H.J. Hepatotoxicity: the adverse effects of drugs and other chemical lives on the r. 2nd Ed. Philadelphia: Lippincott, 681-7 pp. (Expert Review of Hepatotoxicity of Methotrexate Published in 1999).